SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs planned AI-unit rebrand to SpaceXSI and its broader AI-compute ambitions are fueling bullish momentum, with traders also focused on Musks confirmed discussions with TSMC about a possible Terafab collaboration. Optimism over growth and analyst support is countered by concerns about valuation, speculative merger and contract claims, and upcoming share unlocks.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemons steep selloff is drawing attention amid concerns about weak sales and guidance, slowing demand, and growing competition in athleisure. Traders are split between calling the shares oversold and historically cheap, and warning that fading pricing power and a weakening brand could keep the stock under pressure.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulfs expanded Kentucky Power agreement, which doubles planned Muskie data-campus capacity to 1 GW and brings forward the second phase, is drawing attention as part of its AI/HPC growth push. Reactions are split: some see stronger demand and long-term opportunity, while others focus on the selloff despite the news and worry about buildout costs, dilution, and the time needed for revenue to materialize; the agreement still requires regulatory approval.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

OpenAI CEO Sam Altmans description of Cerebras as a close partner has eased concerns after reports that Nvidia GPUs were being used for OpenAIs latest Ultrafast mode, helping drive a rebound in CBRS shares. Traders are largely celebrating the reassurance, while some caution that it does not confirm Cerebras powers that specific mode and point to insider share unlocks and valuation as ongoing risks.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

A sharp selloff has put CMG in focus, with traders pointing to weakness across restaurant and consumer-discretionary stocks amid concerns about rates and pressured consumer spending, alongside recurring complaints about food quality and safety. Bears see more downside, while some traders view the drop as a buying opportunity; no clear fresh company-specific catalyst dominates the discussion.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors 24-month HOPE-3 open-label extension data showing slower upper-limb decline in Duchenne muscular dystrophy is driving discussion as the company seeks FDA approval for a narrowed upper-limb indication. Traders are divided over whether the supportive but nonrandomized data will address the FDAs earlier concerns, with bearish analyst commentary and the stocks weak reaction adding to the debate.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3Ds sharp selloff is being discussed alongside CFO James Suvas sudden departure and the limited explanation for it; traders are split between viewing the transition and interim replacement as manageable and seeing the timing as a warning sign. Some dip buyers call the reaction overdone or blame short-selling, while skeptical holders cite lingering concerns about management and transparency.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Repeated open-market purchases by CEO Ryan Cohen and other insiders are driving bullish attention as GME rises, with traders watching for a technical breakout and speculating that the approaching warrant expiration could intensify short-covering. Others caution that insider buying alone has produced limited follow-through and say a substantive business announcement or stronger volume is needed; the squeeze theories remain speculative.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTXs sharp reversal after strong VK2735 maintenance data is being attributed mainly to the recent equity and convertible financing, with traders citing dilution, hedging-related selling and limited near-term catalysts. Bulls remain encouraged by the obesity-drug data and see the pullback as an accumulation opportunity, while bears question managements financing and go-it-alone strategy and point to competition and a long wait for Phase 3 results.

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

Vaxcyte Inc

Vaxcyte shares surged after its VAX-31 pneumococcal vaccine met all prespecified primary endpoints in the pivotal Phase 3 OPUS-1 trial, including comparisons with competing vaccines. Traders are celebrating the data while debating whether the sharp move invites profit-taking, and some caution that the candidate still faces further trials, regulatory review, and potential dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial

Atea Pharmaceuticals announced positive Phase 3 C-BEYOND trial results for its oral hepatitis C combination therapy vs. Gilead's therapy.read more...

Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know

Atea Pharmaceuticals (AVIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Are Medical Stocks Lagging  Atea Pharmaceuticals (AVIR) This Year?

Here is how Atea Pharmaceuticals, Inc. (AVIR) and Design Therapeutics, Inc. (DSGN) have performed compared to their sector so far this year.

Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround 

Atea Pharmaceuticals (AVIR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript

Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Tuesday

Atea Pharmaceuticals (NASDAQ:AVIR) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-atea-pharmaceuticals-inc-stock...

Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Up 1.6% - Still a Buy?

Atea Pharmaceuticals (NASDAQ:AVIR) Shares Up 1.6% - Time to Buy...

Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Up 5.9% - Here's Why

Atea Pharmaceuticals (NASDAQ:AVIR) Shares Up 5.9% - Time to Buy...

Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 12-Month High - Here's Why

Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 1-Year High - What's Next...

Atea Pharmaceuticals Q4 Earnings Call Highlights

Atea Pharmaceuticals (NASDAQ:AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an update on its newly expanded hepatitis E virus (HEV) pipeline during its...

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

Atea Pharmaceuticals Inc

Neutral Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be this week?

Stocktwits

Stocktwits Polls

$AVIR
Icarus flew too close to the sun apparently and a FUDster has entered our quiet community chat.

Navier_Stokes

$AVIR
Underpriced, unknown to the market masses  , under appreciated yet with  a provenance that includes a very successful USA and Canada Phase 3 result and waiting for rest of world Global Phase 3 results $AVIR  does not trade much over a penny stock.   Let that sink in. Penny stock hitting range with a phase 3 positive result in a compelling profitable area of treatment.   What’s up with that?

Feed

News

Sentiment

Earnings

Fundamentals

Info

AVIR Atea Pharmaceuticals Inc

Fundamentals

Latest AVIR News